Latest Conference Articles

Genetic Testing for Breast Cancer May Benefit Family Members

Genetic Testing for Breast Cancer May Benefit Family Members

March 12th 2024, 10:08pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

An expert explained that patients with breast cancer who undergo genetic testing may help their family members, regardless of whether patients have children.

Patient-Provider Conversations After a Bladder Cancer Diagnosis

Patient-Provider Conversations After a Bladder Cancer Diagnosis

February 5th 2024, 4:00pm

ASCO Gastrointestinal Cancers Symposium

There are a few conversations patients should have with their care teams after being diagnosed with bladder cancer — especially as new treatments become more available.

Slower Infusion of Antiemetic Drugs May Help With Nausea in GI Cancers

Slower Infusion of Antiemetic Drugs May Help With Nausea in GI Cancers

February 2nd 2024, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.

Welireg Delays Kidney Cancer Progression, Betters Quality of Life

Welireg Delays Kidney Cancer Progression, Betters Quality of Life

January 31st 2024, 10:00pm

Uromigos

Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.

Long-Term, High-Dose Radiation, ADT Boosts Survival in Prostate Cancer

Long-Term, High-Dose Radiation, ADT Boosts Survival in Prostate Cancer

January 30th 2024, 8:00pm

ASCO Genitourinary Symposium

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

Kidney Cancer Subtypes, Tumor Stages May Predict Recurrence, Prognosis

Kidney Cancer Subtypes, Tumor Stages May Predict Recurrence, Prognosis

January 30th 2024, 2:00pm

ASCO Genitourinary Symposium

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Injectable Opdivo May Mitigate Disparities in Kidney Cancer

Injectable Opdivo May Mitigate Disparities in Kidney Cancer

January 29th 2024, 11:00pm

ASCO Genitourinary Symposium

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Postsurgical Keytruda Boosts Survival in Clear Cell Renal Cell Carcinoma

Postsurgical Keytruda Boosts Survival in Clear Cell Renal Cell Carcinoma

January 29th 2024, 10:00pm

ASCO Genitourinary Symposium

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Opdivo Misses Disease-Free Survival Goal in Kidney Cancer Trial

Opdivo Misses Disease-Free Survival Goal in Kidney Cancer Trial

January 29th 2024, 5:00pm

ASCO Genitourinary Symposium

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

Adstiladrin Leads to Beneficial Outcomes in Some Bladder Cancers

Adstiladrin Leads to Beneficial Outcomes in Some Bladder Cancers

January 29th 2024, 4:00pm

ASCO Genitourinary Symposium

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.